Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Updates on several important clinical trials were presented at an international ALS conference in December, including reports on ISIS-SOD1-Rx, NP001, neural stem cells, olesoxime and tirasemtiv
Posted on Thursday, December 13, 2012 - 16:11, By: Amy Madsen
The 23rd International Symposium on ALS/MND (motor neuron disease), held in Chicago Dec. 5-7, 2012, brought together more than 900 researchers, clinicians and other health care professionals from 30 countries to hear presentations on the latest in ALS care and research.
Early results show ISIS-SOD1-Rx, an antisense drug directed against the SOD1 form of familial ALS, appears safe in the lowest-dose group
Posted on Wednesday, April 27, 2011 - 16:12, By: Margaret Wahl
Update (July 21, 2014): This study was completed in 2012.
Posted on Tuesday, March 1, 2011 - 09:06, By: ALSN Staff
MDA has awarded eight new grants totaling nearly $2.5 million to fund research into the causes of, and potential therapies for, ALS.
The grants were reviewed and approved by the MDA Board of Directors in December 2010, based on recommendations from the MDA Scientific and Medical Advisory Committees...
Human testing has begun of ISIS-SOD1-Rx, a compound designed to block production of a toxic protein in people with the SOD1-related form of familial (inherited) ALS
Posted on Friday, March 5, 2010 - 15:20, By: Amy Madsen
Isis Pharmaceuticals of Carlsbad, Calif., has begun a phase 1 clinical trial of its experimental compound ISIS-SOD1-Rx in people with familial (inherited) ALS caused by toxic SOD1 protein molecules.
The first ALS trial to block abnormal SOD1 protein using ‘antisense’ is set to open by the end of 2009
Posted on Monday, October 19, 2009 - 13:47, By: ALSN Staff
A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four...